Agastiya Biotech Proceeding with Drug Candidate for COVID-19: Small Molecule Compound for Treatment of SARS-CoV-2
SAN DIEGO--(BUSINESS WIRE)--Agastiya Biotech LLC (www.agastiyabiotech.com) today announces it has discovered its previously tested anti-cancer small molecule AB001 as a viable SARS-CoV-2 virus therapeutic. Based on in silico models, AB001 acts on ACE-2 to inhibit the...
Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19
Vopec Pharmaceuticals has received the NOC (no objection certificate) and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19. It inhibits Angiotensin-converting enzyme-2...
Agastiya Biotech Developing Drugs for Stage IV Cancer and COVID-19
Vopec Pharma and East-West Integrative Research Institute, both based in Chennai India, have received funds and know-how from Agastiya Biotech to develop drugs for Stage IV cancer and COViD-19. Baskaran Pillai PhD., founded Agastiya Biotech with a vison to integrate...
Agastiya Biotech to Bridge U.S. – India Drug Development
Dr. Baskaran Pillai announces the launch of Agastiya Biotech, a biotechnology and new drug development company based in Temecula, CA. Prior to Agasitya Biotech, Dr. Pillai started East West Integrative Research Institute in Chennai, India in 2013, which successfully...
Evaluation of Effect of Topical Application of Ps-35 on Patients Affected with Chronic Plaque Psoriasis: A Clinical Study
Psoriasis is a chronic, immune-mediated, inflammatory relapsing systemic skin disorder that predominantly involves the skin, nails, and joints with intermittent remissions. The disease is resulting from a polygenic predisposition, combined with environmental triggering factors. The worldwide prevalence of psoriasis is estimated to be approximately 2-3% [1]. Prevalence varies according to race, geographic location and environmental factors [2]. About two-thirds of affected individuals suffer from mild psoriasis, whereas about one- third have a more severe involvement.